Dual-Action Theranostic Nanoparticles Delivering Toll-Like Receptor 2 Inhibitors and Chemotherapy Target Breast Cancer Cells and the Tumor Microenvironment - PubMed
3 days ago
- #nanoparticles
- #TLR2-inhibitor
- #breast-cancer
- Breast cancer is the leading cause of cancer-related death in women, often due to therapy resistance.
- Toll-like receptor 2 (TLR2) is overexpressed in breast tumors and promotes cancer progression and chemoresistance.
- Researchers developed dual-action nanoparticles (NPs) combining TLR2 inhibitor CU-CPT22 (PLGA-CU) and doxorubicin-loaded liposomes (LIPO-DOXO).
- Both NPs were functionalized with cyclic RGD peptides to target αvβ3 integrins.
- In vitro and in vivo studies showed PLGA-CU effectively inhibited TLR2 signaling.
- Combined PLGA-CU and LIPO-DOXO treatment reduced cell viability and induced apoptosis more effectively than monotherapies.
- In vivo, the combined treatment targeted both cancer cells and the tumor microenvironment (TME), reducing angiogenesis and immunosuppression.
- The approach offers a promising strategy to overcome chemoresistance in advanced breast cancer.